In response to online comments, the reporter called the securities department of Yiling Pharmaceutical, and the staff told the reporter: "Please point out the specific questions and sources about the news spread in Weibo, and we will answer the specific contents. We have complete evidence and report disclosure from clinical trials, specific experimental data, and the diagnosis and treatment plan included in COVID-19, including indications and instructions. You can't ask questions just because of the word' Wang Sicong'. Just listen to some comments on the internet. Investors please screen. "
Lianhua Qingwen Capsule is a compound Chinese medicine.
According to official website of Yiling Pharmaceutical Co., Ltd., Lianhua Qingwen Capsule/Granule is a patented new drug for treating cold and influenza, which was developed under the guidance of collateral disease theory of traditional Chinese medicine. It is a new drug variety approved by the rapid drug approval channel of the State Pharmaceutical Products Administration, and won the second prize of national scientific and technological progress, and entered the clinical research of the US FDA in treating influenza.